| Filed On | Filing |
|---|---|
| 06 Nov 2026 | FORM 10-Q |
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition
Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue |
| 07 Aug 2026 | 144 |
| 05 Aug 2026 |
Form 4: Fischetti Gary P, Director
Bought 1,000 shares ($20.7K) · Bought 1,000 shares ($20.3K) |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 29 Jul 2026 | FORM S-8 |
| 29 Jul 2026 | FORM 10-Q |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
Commercial Channel Revenue Increased 17% to a Record $13.9 Million |
| 17 Jul 2026 | SCHEDULE 13G/A |
| 14 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
This FIFTH AMENDMENT TO CREDIT AGREEMENT, dated as of July 10, 2026 (this “Fifth Amendment”), is entered into among ANIKA THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the Subsidiary Guarantors party hereto (if any), each ... |
| 23 Jun 2026 |
Form 4: Fischetti Gary P, Director
Received 10,402 shares as a grant or award |
| 23 Jun 2026 |
Form 4: Henneman John B Iii, Director
Received 10,402 shares as a grant or award |
| 23 Jun 2026 |
Form 4: Richard Stephen, Director
Received 10,402 shares as a grant or award |
| 23 Jun 2026 |
Form 4: Capper Joseph H, Director
Received 10,402 shares as a grant or award |
| 23 Jun 2026 |
Form 4: Conley Sheryl L, Director
Received 10,402 shares as a grant or award |
| 23 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan. |
| 08 Jun 2026 | DEFA14A |
| 05 Jun 2026 |
Form 4: Griffin Stephen D., Director
Received 12,840 shares by exercise or conversion · Gave up 3,769 shares to cover exercise price or tax ($54.3K) |
| 01 Jun 2026 | DEFA14A |
| 04 May 2026 |
Form 4: Henneman John B Iii, Director
Bought 5,000 shares ($73.3K) |
Loading...